Edition:
United States

Tenax Therapeutics Inc (TENX.OQ)

TENX.OQ on NASDAQ Stock Exchange Capital Market

6.12USD
20 Apr 2018
Change (% chg)

$-0.07 (-1.13%)
Prev Close
$6.19
Open
$6.18
Day's High
$6.18
Day's Low
$6.08
Volume
5,835
Avg. Vol
55,224
52-wk High
$15.78
52-wk Low
$4.42

Latest Key Developments (Source: Significant Developments)

Tenax Therapeutics Announces Reverse Stock Split
Friday, 23 Feb 2018 08:00am EST 

Feb 23 (Reuters) - Tenax Therapeutics Inc ::TENAX THERAPEUTICS ANNOUNCES REVERSE STOCK SPLIT.TENAX THERAPEUTICS INC - ‍REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-20​.  Full Article

Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies
Tuesday, 16 Jan 2018 07:45am EST 

Jan 16 (Reuters) - Tenax Therapeutics Inc ::TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES.TENAX THERAPEUTICS - PHASE 2 TRIAL TO INVESTIGATE LEVOSIMENDAN IN PULMONARY HYPERTENSION-WHO GROUP 2 PATIENTS WITH PRESERVED EJECTION FRACTION.TENAX THERAPEUTICS INC - PLANS TO INITIATE PHASE 2 TRIAL IN PH-HFPEF PATIENTS IN EARLY PART OF Q3 OF 2018.TENAX THERAPEUTICS INC - ‍PRE-IND MEETING IS SCHEDULED WITH FDA TO DISCUSS DEVELOPMENT OF LEVOSIMENDAN IN PH-HFPEF IN COMING MONTHS​.  Full Article

Tenax Therapeutics says company's board is continuing its review of strategic alternatives
Friday, 28 Jul 2017 05:00pm EDT 

July 28 (Reuters) - Tenax Therapeutics Inc :Tenax Therapeutics provides regulatory update on Levosimendan.Tenax Therapeutics Inc says company's board of directors is continuing its review of strategic alternatives.Tenax Therapeutics Inc - After a review of further analyses, FDA has requested an additional clinical trial.Tenax Therapeutics Inc - Company is reviewing clinical, regulatory and financial options with regard to Levosimendan program in U.S. and Canada..  Full Article

Tenax meets with FDA to discuss positive mortality data and potential levosimendan NDA submission
Tuesday, 16 May 2017 04:33pm EDT 

May 16 (Reuters) - Tenax Therapeutics Inc :Tenax meets with FDA to discuss positive mortality data and potential levosimendan NDA submission.Tenax Therapeutics - Analysis of pre-specified LEVO-CTS subgroup of isolated CABG surgery patients indicates a 73% reduction in 90-day all-cause mortality.Tenax Therapeutics - Mortality reduction in LEVO-CTS isolated CABG patients is consistent with study hypothesis and data from previously published trials.Tenax Therapeutics Inc - FDA requested submission of additional information from published cross study analyses that were presented during meeting.Tenax - Met with FDA on May 10 to review additional data analyses from phase 3 LEVO-CTS clinical study of levosimendan in cardiac surgery patients at LCOS risk.  Full Article

Tenax hires Ladenburg Thalmann to review strategic options
Wednesday, 5 Apr 2017 05:30pm EDT 

Tenax Therapeutics Inc : Tenax Therapeutics announces review of strategic alternatives and business update . Tenax Therapeutics - Ladenburg Thalmann engaged to assist in process . Tenax Therapeutics - John Kelley resigns as CEO; Michael Jebsen, president and CFO, appointed as interim CEO . Tenax Therapeutics - company continues to evaluate results of LEVO-CTS clinical trial .Tenax - strategic review process includes merger, business combination, strategic investment into co, purchase, license or other acquisition of assets.  Full Article

Tenax Therapeutics had $21.9 mln in cash as of December 31, 2016
Tuesday, 21 Mar 2017 06:00am EDT 

Tenax Therapeutics Inc : Tenax Therapeutics announces year-end 2016 financial results and provides corporate update . Tenax Therapeutics Inc- expects cash balance will be sufficient for it to accomplish its corporate goals through first half of 2018 .Tenax Therapeutics Inc- as of December 31, 2016, company had $21.9 million in cash compared to $38.2 million at December 31, 2015.  Full Article

Tenax Therapeutics announces top-line results from phase 3 LEVO-CTS trial in cardiac surgery
Tuesday, 31 Jan 2017 09:00am EST 

Tenax Therapeutics Inc : Tenax Therapeutics announces top-line results from phase 3 levo-cts trial in cardiac surgery . Tenax Therapeutics Inc - study did not achieve statistically significant reductions in dual or quad primary endpoints . Says has a meeting scheduled with U.S. Food and drug administration (FDA) to review preliminary trial data . Tenax Therapeutics Inc - patient visits for data on death through day 90 have not yet been completed . Tenax Therapeutics Inc- has a meeting scheduled with u.s. Food and drug administration (FDA) to review preliminary trial data . Tenax Therapeutics - study met two secondary endpoints with statistically significant reduction in incidence of lcos, use of postoperative secondary inotropes .Says "we continue to review full data set".  Full Article

Tenax Therapeutics completes enrollment in late-stage cardiac study
Friday, 18 Nov 2016 08:30am EST 

Tenax Therapeutics Inc : Tenax therapeutics inc says 880 total patients enrolled; top-line data readout currently expected in january 2017 .Tenax therapeutics announces completion of enrollment for phase 3 levo-cts trial in cardiac surgery.  Full Article

Tenax Therapeutics q2 loss per share $0.17
Thursday, 11 Aug 2016 06:00am EDT 

Tenax Therapeutics Inc : Tenax therapeutics announces second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.17 . Currently anticipates that its cash balance at end of 2016 will be between $19 million and $20 million .Continues to expect that its cash balance will be sufficient for it to accomplish its corporate goals through 2017.  Full Article

Tenax Therapeutics Q1 loss per share $0.19
Thursday, 19 May 2016 06:30am EDT 

Tenax Therapeutics Inc : Continues to expect that its cash balance will be sufficient for it to accomplish its corporate goals through 2017 . Tenax therapeutics announces first quarter 2016 financial results and provides corporate update .Q1 loss per share $0.19.  Full Article

BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies

* TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES